University of California San Francisco School of Medicine, San Francisco, CA, USA.
Section of Cardiology, Department of Medicine, San Francisco Veterans Affairs Medical Center, 4150 Clement St, 111C, San Francisco, CA, 94121, USA.
J Interv Card Electrophysiol. 2023 Jun;66(4):997-1004. doi: 10.1007/s10840-022-01189-x. Epub 2022 Mar 25.
Post-market evaluation is important to ensure the ongoing safety and effectiveness of cardiovascular implantable electronic device (CIED) leads. The Twenty-First Century Cures Act and subsequent Food and Drug Administrative (FDA) Guidance provide an opportunity to leverage real-world data sources for this purpose. The past 4 years have seen the development of EP PASSION: a multi-stakeholder, collaborative effort between the FDA, CIED manufacturers, Heart Rhythm Society, and academics. Using real-world data, EP PASSION enables longitudinal evaluation of the long-term safety of CIED leads, addressing limitations of current approaches to generate evidence that informs regulatory, clinical, and manufacturer decision-making. This state of the art article describes the impetus for and launch of EP PASSION, the lessons learned, its current state, the current analytic approach, and the strengths and limitations of leveraging extant data sources for post-market lead evaluation. We also compare EP PASSION to traditional post-approval studies and describe possible future directions.
上市后评估对于确保心血管植入式电子设备(CIED)导线的持续安全性和有效性非常重要。《21 世纪治愈法案》和随后的食品和药物管理局(FDA)指南为此提供了利用真实世界数据源的机会。在过去的 4 年中,已经开发出 EP PASSION:这是 FDA、CIED 制造商、心律学会和学术界之间的多利益相关者、协作努力。使用真实世界的数据,EP PASSION 能够对 CIED 导线的长期安全性进行纵向评估,解决当前方法在生成证据方面的局限性,为监管、临床和制造商决策提供信息。本文详细描述了 EP PASSION 的启动背景、经验教训、现状、当前分析方法,以及利用现有数据源进行上市后导线评估的优势和局限性。我们还将 EP PASSION 与传统的上市后研究进行了比较,并描述了可能的未来方向。